News | July 26, 2023
Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Good momentum in commercial CDMO business
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Subscribe To Our Newsletter & Stay Updated
